Dianthus Therapeutics | MGTA - Ebit


Dianthus Therapeutics reported $-40.29M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Avita Medical AUD -8.66M 1.61M Jun/2025
Celltrion KRW 301.04B 58.57B Sep/2025
Cspc Pharmaceutical CNY 1.22B 60.54M Sep/2025
Dianthus Therapeutics USD -40.29M 5.36M Sep/2025
Divis Laboratories Ltd INR 7.75B 1.58B Sep/2025
IQVIA Holdings USD 573M 17M Sep/2025
Kangmei Pharma CNY -26.7M 43.13M Sep/2025
Knight Therapeutics CAD 3.2M 1.29M Sep/2024
Laboratorios Farma EUR 135.05M 49.84M Dec/2023
Malin Corporation EUR -1.1M 300K Dec/2024
Medical Developments International AUD -12.12M 3.97M Jun/2023
Moderna USD -260M 557M Sep/2025
Neuren Pharmaceuticals AUD 171.1M 159.25M Dec/2024
Organigram Holdings CAD -28.05M 25.94M Sep/2025
Organon & Co USD 388M 28M Sep/2025
Pharma Mar EUR -3.96M 28.11M Sep/2025
Qiagen NV USD 141.06M 6.64M Sep/2025
Revvity USD 98.34M 7.58M Sep/2025
Sartorius EUR 150.1M 11.7M Sep/2025
Sino Biopharmaceutical CNY 5.18B 3.32B Jun/2025
Tectonic Therapeutic USD -22.33M 4.03M Jun/2025
Tilray USD -20.01M 9.34M Sep/2025
Viatris USD 234.5M 49.1M Sep/2025
Xeris Pharmaceuticals USD 7.89M 2.46M Sep/2025
Zz Pientze Pharmaceu CNY 501.33M 15.6M Sep/2025